" class="no-js "lang="en-US"> Sobi - Medtech Alert
Wednesday, March 22, 2023
Sobi | Pharmtech Focus


About Sobi


Sobi is a specialised international biopharmaceutical company transforming the lives of people with rare diseases. We are providing sustainable access to innovative therapies in the areas of haematology, immunology and specialty indications. Today, we employ approximately 1,500 people across Europe, North America, Middle East and Asia. In 2020, our revenue amounted to SEK 15.3 billion. The Sobi share (STO:SOBI) is listed on Nasdaq Stockholm. You can find more information about Sobi at sobi.com.

Related Story

ADC Therapeutics and Sobi Announce European Commission Approval of ZYNLONTA® for the Treatment of Lymphoma

December 21 2022

ADC Therapeutics SA and Swedish Orphan Biovitrum AB (Sobi) has announced the European Commission (EC) […]

Sobi Continues the R&D Transformation - Anders Ullman Appointed New Head of R&D

December 13 2021

Anders Ullman, M.D., Ph.D., currently a member of the Board of Directors of Sobi, will […]